A Cross-sectional Analysis of Adverse Events and Litigation for Injectable Fillers
Authors:
Top Cited Papers
- 17 May 2018
- journal article
- conference paper
- Published by SAGE Publications in JAMA Facial Plastic Surgery
- Vol. 20 (3) , 207-214
Abstract
Importance: Injectable fillers are increasing in popularity as a noninvasive option to address concerns related to facial aging and volume loss. To our knowledge, there have been no large-scale analyses of adverse events and associated litigation related to filler injections. Objectives: To determine risks of injectable fillers and analyze factors raised in litigation related to injectable fillers. Design, Setting, and Participants: In this cross-sectional review, the US Food and Drug Administration’s (FDA) manufacturer and user facility device experience (MAUDE) database was evaluated for complications from the use of the following fillers: Juvederm, Restylane, Belotero, Sculptra, Radiesse, Artefill, Bellafill, and Juvederm Voluma from 2014 to 2016. The Westlaw Next database was used to identify jury verdicts. Main Outcomes and Measures: Complications were organized by type of filler used, location of injection, and severity. Intra-arterial injections without sequelae and those resulting in blindness or necrosis were considered severe complications. Factors raised during the litigation process were also analyzed. Results: Of 1748 adverse events analyzed, most cases stemmed from cheek (751 [43.0%]) or lip (524 [30.0%]) injection. Commonly reported adverse events reported included swelling (755 [43.2%]) and infection (725 [41.5%]). Among FDA-reported complications, blindness was significantly associated with dorsal nasal injections ( P < .001). Vascular compromise with and without sequela of dermal necrosis and blindness were significantly associated with Radiesse injections P < .001. Of the 9 malpractice cases identified, two-thirds involved allegations of inadequate informed consent, and the median award in cases resolved with payment was $262 000. Conclusions and Relevance: Although specific complication profiles vary by material and injection site, common adverse events associated with injectable fillers include swelling and infection. More serious events include vascular compromise, resulting in necrosis and blindness; these events are also raised in cases involving litigation. This analysis illustrates the importance of outlining these risks in a comprehensive preoperative informed consent process. Level of Evidence: NA .Keywords
This publication has 45 references indexed in Scilit:
- Dermal fillers in aesthetics: an overview of adverse events and treatment approachesClinical, Cosmetic and Investigational Dermatology, 2013
- Physician accountability in iatrogenic cerebrospinal fluid leak litigationInternational Forum of Allergy & Rhinology, 2013
- Thyroidectomy‐Related Malpractice ClaimsOtolaryngology–Head and Neck Surgery, 2012
- Cosmetic Use of Poly-l-lactic Acid: My Technique for Success and Minimizing ComplicationsDermatologic Surgery, 2011
- A Multicenter, 47-Month Study of Safety and Efficacy of Calcium Hydroxylapatite for Soft Tissue Augmentation of Nasolabial Folds and Other Areas of the FaceDermatologic Surgery, 2007
- Letter: NewFill for Skin Augmentation: A New Filler or Failure?Dermatologic Surgery, 2006
- Claims, Errors, and Compensation Payments in Medical Malpractice LitigationNew England Journal of Medicine, 2006
- Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophyJournal of the American Academy of Dermatology, 2005
- The History of Substances for Soft Tissue AugmentationDermatologic Surgery, 2000
- Ultrastructure of the Human Dermal Microcirculation. IV. Valve-Containing Collecting Veins at the Dermal–Subcutaneous JunctionJournal of Investigative Dermatology, 1983